demonstrated that Notch-3 dependent β-catenin signal stabilization mediated cancer cell survival against an early treatment with EGFR inhibitors, which they referred to as ‘adaptive persisters’, and discovered that combinatorial treatment against β-catenin and EGFR provided enhanced tumor control. The gene discussed is NOTCH3; the disease is cancer.